TNDM
Tandem Diabetes Care Inc
16.20$
-2.2%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 154.5% | 78.7% | 69.3% | 63.5% | 72.0% | 59.0% | 51.1% | 46.4% | 47.8% | 46.5% | 48.5% | 50.8% | 47.9% | 47.7% | |
| – | -54.5% | 21.3% | 30.7% | 36.5% | 28.0% | 41.0% | 48.9% | 53.6% | 52.2% | 53.5% | 51.5% | 49.2% | 52.1% | 52.3% | |
| – | 364.0% | 38.2% | 31.8% | 23.3% | 22.3% | 19.2% | 15.9% | 12.5% | 12.7% | 13.1% | 21.2% | 33.2% | 21.2% | 17.2% | |
| – | 914.2% | 151.1% | 151.1% | 107.9% | 98.3% | 80.3% | 57.2% | 45.7% | 41.1% | 37.2% | 41.9% | 47.1% | 41.5% | 43.9% | |
| – | 1,281.0% | 191.7% | 182.8% | 131.2% | 120.6% | 99.5% | 73.1% | 58.2% | 53.8% | 50.3% | 63.1% | 80.4% | 62.6% | 60.0% | |
| – | -1,335.4% | -170.4% | -152.2% | -94.7% | -92.6% | -58.5% | -24.3% | -4.6% | -1.6% | 3.2% | -11.6% | -31.2% | -10.5% | -7.7% | |
| – | 102.0% | 16.2% | 7.8% | 5.1% | 6.8% | 10.5% | 4.1% | 0.0% | 2.4% | 0.9% | 0.8% | 1.3% | 0.8% | 0.8% | |
| – | -1,334.1% | -217.7% | -159.8% | -99.4% | -99.1% | -67.9% | -66.7% | -6.8% | -7.3% | 2.3% | -11.6% | -29.5% | -9.8% | -19.7% | |
| – | 102.0% | 16.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.4% | 0.0% | 0.2% | 0.3% | 0.4% | 0.4% | |
| – | -1,334.1% | -217.7% | -159.9% | -99.4% | -99.0% | -67.9% | -66.7% | -6.8% | -6.9% | 2.2% | -11.8% | -29.8% | -10.2% | -20.2% | |
| – | -1,149.9% | -190.5% | -143.3% | -88.1% | -86.1% | -52.1% | -21.1% | -2.9% | 0.5% | 4.8% | -9.3% | -26.3% | -10.5% | -17.2% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.